Blood Serum vs. Urine: Why the Sample Type Matters
Urine mycotoxin testing has documented limitations. Blood serum antibody testing measures what urine testing cannot: Your immune system’s actual response to mycotoxin exposure.
Most mycotoxin testing in the U.S. relies on urine samples. Urine tests detect mycotoxin metabolites; trace amounts of toxin compounds passing through the body at the time of collection, not the actual mycotoxins themselves. According to the National Institute for Occupational Safety and Health (NIOSH), a part of the CDC, low levels of mycotoxins are found in many common foods. The United Nations Food and Agriculture Organization and the World Health Organization estimate that 25% of the world’s crops are contaminated by mold. As a result, mycotoxins can be found in the urine of healthy people, meaning a positive urine result does not necessarily indicate illness, and a negative result does not rule out meaningful exposure. [1][7]
Blood serum testing eliminates this ambiguity. Instead of measuring traces of toxins, it measures IgG and IgE antibodies — the immune system’s specific response to mycotoxins it has recognized as a threat. An antibody response means exposure was significant enough for the body to react. This is the difference between detecting what passed through and understanding what caused harm. [1][2][3]
Urine testing measuring what has left the body. Blood serum testing measures what is in the body and reveals what your body is actively responding to.
How the Two Methods Compare
The table below breaks down the key differences between blood serum antibody testing and urine mycotoxin testing across the factors that matter most for accurate diagnosis.
Blood Serum Testing
Urine Testing (Other Labs)
What it measures
IgG and IgE antibodies: Your immune system's response to mycotoxin exposure [1][2]
Free mycotoxin metabolites: Toxin compounds passing through the body [1][2]
What results tell you
Whether your body has mounted an immune reaction to specific mycotoxins indicating clinically meaningful exposure [2][3]
Whether mycotoxin compounds are present in your urine at the time of collection [1]
Ochratoxin A detection
Reliable. Detected through antibodies in the blood [4][5]
Unreliable. 99.8% of ochratoxin binds to albumin and is reabsorbed by the kidneys, making urinary excretion negligible [1][4]
Dietary mycotoxin interference
Not a factor. antibodies reflect immune response, not food intake [1][6]
Significant confounder. Can detect traces from everyday foods (cereals, coffee, nuts, wine), even in healthy individuals [1][7]
Exposure vs. presence
Distinguishes between clinically significant immune exposure and incidental contact [1][6]
Detects presence but cannot differentiate between dietary intake and environmental exposure [1][7]
Antibody differentiation
Tests both IgG (past/ongoing exposure) and IgE (allergic sensitization) for each mycotoxin [2][3]
Not applicable. Urine testing does not measure immune response [1]
Mast cell activation relevance
IgE antibodies to specific mycotoxins can indicate active allergic sensitization. Directly relevant for clinicians evaluating patients with suspected Mast Cell Activation Syndrome (MCAS) [2][3]
No mast cell data. Urine metabolite testing does not measure allergic sensitization or mast cell related immune activity
Number of mycotoxins tested
14 mycotoxins with both IgG and IgE delivering 28 individual results
Typically 11–16 mycotoxins, varies by laboratory
Exposure timeline
IgG antibodies can remain elevated for months to years, reflecting long-term exposure history [2][3]
Reflects recent exposure only. The results vary based on daily intake and timing of collection [4]
Clinical validation
Serum antibody methodology validated in peer-reviewed research for over 20 years [1][6]
Methodology varies by lab; the CDC has noted limitations of urine-based mycotoxin testing for clinical diagnosis [7]
Sample type
Blood draw (via phlebotomist)
Urine collection (at home)
Best suited for
Clinicians and patients who need to confirm whether mycotoxin exposure has triggered an immune response which is the clinical standard for diagnosing mycotoxin-related illness.
General screening for recent mycotoxin presence; limited diagnostic value for confirming clinically meaningful exposure
● The Ochratoxin: A Problem
Why Ochratoxin A Is the Strongest Case for Blood Serum Testing
If there is a single mycotoxin that exposes the limitations of urine testing, it is Ochratoxin A. It is one of the most widespread, most dangerous, and most clinically important mycotoxins to test for. And it is the one urine testing is least equipped to detect.
The science is straightforward: Almost all ochratoxin A in the body (99.8%) binds to albumin, the main protein in blood. Once bound, it is reabsorbed from all parts of the nephron by both active transport and passive diffusion, making elimination through glomerular filtration negligible. In plain terms: the kidneys cannot filter it out, so it does not show up in urine in meaningful amounts. [1][4]
A urine test can return a low or negative result for ochratoxin A even when the patient’s blood contains significant levels. Relying on urine alone for this toxin can give false reassurance and delay diagnosis. [8]
Why Ochratoxin A matters clinically:
Ochratoxin A is nephrotoxic, hepatotoxic, neurotoxic, immunotoxic, genotoxic, and carcinogenic. It has been classified as a possible human carcinogen (IARC Group 2B) since 1993. Long-term low-level exposure can be more damaging than a single acute dose. It crosses the placenta, concentrates in breast milk, and has been documented to cause acute renal failure within 24 hours of inhalation exposure. Emerging research links it to Parkinson’s disease and autism spectrum disorder in children. [4]
This is not a minor gap in urine testing. It is a fundamental limitation. Any mycotoxin panel that relies on urine cannot reliably assess exposure to one of the most clinically significant toxins on the list. Blood serum antibody testing detects Ochratoxin A through the immune response it triggers, regardless of how the body processes the toxin itself.
For Patients
Create a patient account, order your test kit, and get results delivered to your secure portal. No doctor's order needed, though we recommend sharing your results with a healthcare provider to guide next steps.
For Practitioners
Register as a clinician to access your provider portal, order test kits to your office or ship directly to patients, and receive results under your account. A step-by-step Clinician Guide is included with your registration.
● References
[1] Campbell AW. Lyme Disease and Mycotoxicosis: How to Differentiate Between the Two. Altern Ther Health Med. 2019;25(4):8-10.
[2] Vojdani A, Thrasher JD, Madison RA, et al. Antibodies to molds and satratoxin in individuals exposed in water-damaged buildings. Arch Environ Health. 2003;58(7):421-432.
[3] Vojdani A, Campbell AW, Kashanian A, et al. Antibodies against molds and mycotoxins following exposure to toxigenic fungi in a water-damaged building. Arch Environ Health. 2003;58(6):324-336.
[4] Malir F, Ostry V, Pfohl-Leszkowicz A, et al. Ochratoxin A: 50 Years of Research. Toxins (Basel). 2016;8(7):191.
[5] Brasel TL, Campbell AW, Demers RE, et al. Detection of trichothecene mycotoxins in sera from individuals exposed to Stachybotrys chartarum in indoor environments. Arch Environ Health. 2004;59(6):317-323.
[6] Campbell AW, Thrasher JD, Gray MR, Vojdani A. Mold and mycotoxins: effects on neurological and immune systems in humans. Adv Appl Microbiol. 2004;55:375-406.
[7] NIOSH/CDC. As cited in Campbell AW, 2019 [1]: “According to the National Institute for Occupational Safety and Health (NIOSH), a part of the CDC, low levels of mycotoxins are found in many foods.” See also: “Use of Unvalidated Urine Mycotoxin Tests for the Clinical Diagnosis of Illness — United States, 2014.” CDC MMWR.
[8] Campbell AW, Watson P. Mold, Mycotoxins, and their Effects in Children. Altern Ther Health Med. 2021;27(1):8-10.